S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
Positive News SentimentPositive News
NASDAQ:CGEM

Cullinan Oncology (CGEM) Stock Forecast, Price & News

$10.03
+0.34 (+3.51%)
(As of 11:07 AM ET)
Compare
Today's Range
$9.59
▼
$10.06
50-Day Range
$9.49
▼
$11.35
52-Week Range
$7.78
▼
$13.98
Volume
19,104 shs
Average Volume
237,630 shs
Market Capitalization
$428.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Cullinan Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
173.5% Upside
$26.50 Price Target
Short Interest
Bearish
9.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$8,653 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.14) to ($4.23) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

637th out of 961 stocks

Biological Products, Except Diagnostic Industry

104th out of 161 stocks

See Top Rated MarketRank™ Stocks Here

CGEM stock logo

About Cullinan Oncology (NASDAQ:CGEM) Stock

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Price History

CGEM Stock News Headlines

September 16, 2023 | americanbankingnews.com
Short Interest in Cullinan Oncology, Inc. (NASDAQ:CGEM) Expands By 33.2%
September 11, 2023 | msn.com
Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
August 11, 2023 | markets.businessinsider.com
BTIG Sticks to Their Buy Rating for Cullinan Management (CGEM)
August 10, 2023 | finance.yahoo.com
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 9, 2023 | finance.yahoo.com
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 3, 2023 | finance.yahoo.com
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
July 7, 2023 | markets.businessinsider.com
Analyst Ratings for Cullinan Oncology
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
July 7, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Cullinan Management (CGEM)
June 15, 2023 | msn.com
TD Cowen Initiates Coverage of Cullinan Oncology (CGEM) with Outperform Recommendation
June 15, 2023 | markets.businessinsider.com
Analyst Expectations for Cullinan Oncology's Future
June 15, 2023 | markets.businessinsider.com
Expert Ratings for Cullinan Oncology
June 9, 2023 | finance.yahoo.com
Why Shares of Cullinan Oncology Jumped This Week
June 7, 2023 | markets.businessinsider.com
Cullinan Management (CGEM) Receives a Buy from SVB Securities
June 5, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Cullinan Management (CGEM)
May 30, 2023 | markets.businessinsider.com
Cullinan Management (CGEM) Gets a Buy from BTIG
May 26, 2023 | msn.com
HC Wainwright & Co. Reiterates Cullinan Oncology (CGEM) Buy Recommendation
May 26, 2023 | msn.com
Cullinan gains as early trial for cancer drug indicates complete remission
May 25, 2023 | finance.yahoo.com
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 15, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Cullinan Management (CGEM)
May 12, 2023 | msn.com
HC Wainwright & Co. Maintains Cullinan Oncology (CGEM) Buy Recommendation
May 11, 2023 | finance.yahoo.com
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
April 26, 2023 | finance.yahoo.com
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 20, 2023 | finance.yahoo.com
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
April 2, 2023 | benzinga.com
Cullinan Oncology Inc (CGEM) is down -2.57% in a Week, Should You Accumulate?
March 27, 2023 | markets.businessinsider.com
What 4 Analyst Ratings Have To Say About Cullinan Oncology
See More Headlines
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGEM Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGEM
CUSIP
N/A
CIK
1789972
Web
www.cullinanoncology.com
Phone
617-410-4650
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.50
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+164.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$111.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.92%
Return on Assets
-25.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.32
Quick Ratio
25.32

Sales & Book Value

Annual Sales
$18.94 million
Price / Sales
22.63
Cash Flow
$2.58 per share
Price / Cash Flow
3.89
Book Value
$11.73 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
42,740,000
Free Float
38,966,000
Market Cap
$428.68 million
Optionable
Not Optionable
Beta
0.15
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Nadim AhmedMr. Nadim Ahmed (Age 55)
    Pres, CEO & Director
    Comp: $1.14M
  • Dr. Patrick A. Baeuerle Ph.D. (Age 65)
    Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
    Comp: $763.73k
  • Mr. Jeffrey TrigilioMr. Jeffrey Trigilio (Age 38)
    CFO & Treasurer
    Comp: $727.99k
  • Dr. Jennifer Michaelson Ph.D. (Age 55)
    Chief Scientific Officer
  • Ms. Jacquelyn L. Sumer J.D. (Age 44)
    Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
  • Ms. Rose Weldon
    Sr. VP of Communications
  • Mr. Steve Andre
    Chief HR Officer
  • Dr. Corinne Savill Ph.D. (Age 64)
    Chief Bus. Officer
  • Dr. Jeffrey Jones M.B.A. (Age 51)
    M.D., M.P.H., Chief Medical Officer
  • Mr. Kevin A. Johnston
    Chief Technical Operations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CGEM Stock - Frequently Asked Questions

Should I buy or sell Cullinan Oncology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEM shares.
View CGEM analyst ratings or view top-rated stocks.

What is Cullinan Oncology's stock price forecast for 2023?

4 brokerages have issued 12-month price targets for Cullinan Oncology's stock. Their CGEM share price forecasts range from $19.00 to $34.00. On average, they predict the company's stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price.
View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts.

How have CGEM shares performed in 2023?

Cullinan Oncology's stock was trading at $10.55 at the beginning of 2023. Since then, CGEM stock has decreased by 4.9% and is now trading at $10.03.
View the best growth stocks for 2023 here.

Are investors shorting Cullinan Oncology?

Cullinan Oncology saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,650,000 shares, an increase of 33.2% from the August 15th total of 1,990,000 shares. Based on an average daily trading volume, of 258,700 shares, the days-to-cover ratio is currently 10.2 days. Currently, 9.8% of the company's stock are sold short.
View Cullinan Oncology's Short Interest.

When is Cullinan Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CGEM earnings forecast.

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.17.

When did Cullinan Oncology IPO?

(CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Cullinan Oncology's stock symbol?

Cullinan Oncology trades on the NASDAQ under the ticker symbol "CGEM."

Who are Cullinan Oncology's major shareholders?

Cullinan Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include CHI Advisors LLC (7.99%), Franklin Resources Inc. (5.93%), BlackRock Inc. (5.35%), Braidwell LP (4.47%), American International Group Inc. (3.14%) and Kennedy Capital Management LLC (1.27%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2.
View institutional ownership trends.

How do I buy shares of Cullinan Oncology?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cullinan Oncology's stock price today?

One share of CGEM stock can currently be purchased for approximately $10.03.

How much money does Cullinan Oncology make?

Cullinan Oncology (NASDAQ:CGEM) has a market capitalization of $428.68 million and generates $18.94 million in revenue each year. The company earns $111.21 million in net income (profit) each year or ($3.37) on an earnings per share basis.

How can I contact Cullinan Oncology?

The official website for the company is www.cullinanoncology.com. The company can be reached via phone at 617-410-4650 or via email at investors@cullinanoncology.com.

This page (NASDAQ:CGEM) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -